Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower specific behaviour: Agitation ‐ clinically important change (PANSS… compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).
1 finding from 1 review
Global state: CGI‐S change score up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Adverse effects: one or more adverse effects during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse effects during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (very low certainty).
1 finding from 1 review
Somnolence · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower adverse effects: somnolence during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes repeated need for tranquillisation ‐ needing additional injections… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes specific behaviour: Agitation ‐ clinically important change (PANSS… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower global state: non‐responders to the first injection compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes repeated need for tranquillisation ‐ needing additional injections… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes specific behaviour: Agitation ‐ clinically important change (PANSS… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
CBT showed no clear difference in global state: relapse compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Patient readmissions · patients with schizophrenia
CBT showed no clear difference in global state: rehospitalisation* compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Mental state: General ‐ clinically important change (no improvement) · patients with schizophrenia
CBT showed no clear difference in mental state: General ‐ clinically important change (no improvement) compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Adverse effect/event: death ‐ any cause · patients with schizophrenia
CBT showed no clear difference in adverse effect/event: death ‐ any cause compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Social functioning · patients with schizophrenia
1 finding from 1 review